Page last updated: 2024-12-07
sr 57227a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 131747 |
| CHEMBL ID | 90472 |
| CHEBI ID | 92163 |
| SCHEMBL ID | 4234263 |
| MeSH ID | M0220999 |
Synonyms (43)
| Synonym |
|---|
| CHEMBL90472 |
| BB 0248183 |
| 6'-chloro-3,4,5,6-tetrahydro-2h-[1,2']bipyridi nyl-4-ylamine |
| BRD-K09397065-001-01-6 |
| BIOMOL-NT_000141 |
| lopac-s-1688 |
| tocris-1205 |
| NCGC00015931-01 |
| NCGC00025037-01 |
| LOPAC0_001066 |
| BPBIO1_000244 |
| sr57227a |
| NCGC00025037-03 |
| NCGC00025037-02 |
| NCGC00015931-05 |
| 1-(6-chloropyridin-2-yl)piperidin-4-amine |
| NCGC00015931-04 |
| CCG-205143 |
| NCGC00015931-06 |
| NCGC00015931-02 |
| NCGC00015931-03 |
| 4-piperidinamine, 1-(6-chloro-2-pyridinyl)- |
| 77145-51-8 |
| AKOS016343057 |
| gtpl4316 |
| 4-amino-1-(6-chloro-2-pyridyl)piperidine |
| DTXSID8046953 |
| SCHEMBL4234263 |
| tox21 110263 |
| CHEBI:92163 |
| 1-(6-chloro-2-pyridyl)piperidin-4-amine |
| sr-57227 |
| Z1269207553 |
| Q15410185 |
| BRD-K09397065-003-03-8 |
| 1-(6-chloranylpyridin-2-yl)piperidin-4-amine |
| 1-(6-chloro-2-pyridinyl)-4-piperidinamine |
| S4TP4PN22Y , |
| SDCCGSBI-0051036.P002 |
| SY264793 |
| mfcd05662317 |
| unii-s4tp4pn22y |
| EN300-3540903 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| tertiary amino compound | A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. |
| dialkylarylamine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (16)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 0.4467 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 15.8489 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 1.9953 | 0.0282 | 7.0559 | 15.8489 | AID895; AID928 |
| GLS protein | Homo sapiens (human) | Potency | 0.6310 | 0.3548 | 7.9355 | 39.8107 | AID624146 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 39.8107 | 0.0013 | 18.0743 | 39.8107 | AID926 |
| arylsulfatase A | Homo sapiens (human) | Potency | 3.0131 | 1.0691 | 13.9551 | 37.9330 | AID720538 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 14.9763 | 0.0020 | 7.5337 | 39.8107 | AID891 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 17.7828 | 0.0010 | 6.0009 | 35.4813 | AID943; AID944 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 12.5893 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 0.5623 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | Ki | 0.1030 | 0.0010 | 0.8835 | 9.9000 | AID6335 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | Ki | 0.1030 | 0.0010 | 0.8711 | 9.9000 | AID6335 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 0.1030 | 0.0001 | 0.8363 | 10.0000 | AID6335 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 0.1030 | 0.0000 | 0.7411 | 9.9000 | AID6335 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | Ki | 0.1030 | 0.0010 | 0.8835 | 9.9000 | AID6335 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | Ki | 0.1030 | 0.0010 | 0.8835 | 9.9000 | AID6335 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (59)
Molecular Functions (14)
Ceullar Components (18)
Bioassays (18)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID6335 | Binding affinity towards 5-hydroxytryptamine 3 receptor | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Electrostatic potential surfaces of 5-HT(3)R agonists suggest accessory cation-pi site adjacent to agonist binding domain. |
| AID6329 | Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Electrostatic potential surfaces of 5-HT(3)R agonists suggest accessory cation-pi site adjacent to agonist binding domain. |
| AID6327 | Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available | 2002 | Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19 | Electrostatic potential surfaces of 5-HT(3)R agonists suggest accessory cation-pi site adjacent to agonist binding domain. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.51) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||